{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:08Z","timestamp":1787387048452,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NCT12345678"],"award-info":[{"award-number":["NCT12345678"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["NCT12345678"],"award-info":[{"award-number":["NCT12345678"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03623-2","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:52:33Z","timestamp":1781081553000},"page":"4023-4041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04550962","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-2346","authenticated-orcid":false,"given":"Jorge F.","family":"M\u00e1spero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5880","authenticated-orcid":false,"given":"Rand K.","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-721X","authenticated-orcid":false,"given":"Leslie","family":"Vargas-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7441-7621","authenticated-orcid":false,"given":"Hassan","family":"Mobayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-438X","authenticated-orcid":false,"given":"Bassam","family":"Mahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-3910","authenticated-orcid":false,"given":"Carla","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3666-7360","authenticated-orcid":false,"given":"Amir","family":"Bar-Shai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-0129","authenticated-orcid":false,"given":"Mariko S.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9756-1336","authenticated-orcid":false,"given":"Sherif","family":"Zaghloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-4939","authenticated-orcid":false,"given":"Jason H.","family":"Kwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dewhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-5363","authenticated-orcid":false,"given":"Mona S.","family":"Al-Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"3623_CR1","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2024. https:\/\/ginasthma.org\/2024-report. Accessed May 08, 2025."},{"issue":"1","key":"3623_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.200807-1126oc","volume":"179","author":"PM O\u2019Byrne","year":"2009","unstructured":"O\u2019Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179(1):19\u201324. https:\/\/doi.org\/10.1164\/rccm.200807-1126oc.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3623_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","volume":"6","author":"H Ortega","year":"2018","unstructured":"Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-6.e1. https:\/\/doi.org\/10.1016\/j.jaip.2017.12.019.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"3623_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/thorax-2021-217032","volume":"78","author":"S Soremekun","year":"2023","unstructured":"Soremekun S, Heaney LG, Skinner D, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study. Thorax. 2023;78(7):643\u201352. https:\/\/doi.org\/10.1136\/thorax-2021-217032.","journal-title":"Thorax"},{"issue":"8","key":"3623_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060160","volume":"12","author":"N Roche","year":"2022","unstructured":"Roche N, Garcia G, de Larrard A, et al. Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France. BMJ Open. 2022;12(8):e060160. https:\/\/doi.org\/10.1136\/bmjopen-2021-060160.","journal-title":"BMJ Open"},{"issue":"1","key":"3623_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002006","volume":"11","author":"G Tomisa","year":"2024","unstructured":"Tomisa G, S\u00e1nta B, Horv\u00e1th A, et al. Risk of exacerbation and mortality in asthma: a 10-year retrospective financial database analysis of the Hungarian Health Insurance Fund. BMJ Open Respir Res. 2024;11(1):e002006. https:\/\/doi.org\/10.1136\/bmjresp-2023-002006.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"3623_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma\u2013present in most, absent in many. Nat Rev Immunol. 2015;15(1):57\u201365. https:\/\/doi.org\/10.1038\/nri3786.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3623_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-021-00146-9","volume":"19","author":"GW Canonica","year":"2021","unstructured":"Canonica GW, Blasi F, Crimi N, et al. Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. Clin Mol Allergy. 2021;19(1):5. https:\/\/doi.org\/10.1186\/s12948-021-00146-9.","journal-title":"Clin Mol Allergy"},{"issue":"1","key":"3623_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4168\/aair.2025.17.1.47","volume":"17","author":"J Yoon","year":"2025","unstructured":"Yoon J, Yang HJ, Rhee EH, et al. Longitudinal trajectories of asthma and allergic comorbidities in the Korean Childhood Asthma Study. Allergy Asthma Immunol Res. 2025;17(1):47\u201359. https:\/\/doi.org\/10.4168\/aair.2025.17.1.47.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"14","key":"3623_CR10","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3623_CR11","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3623_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666x.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666x.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3623_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"10039","key":"3623_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(16)30307-5.","journal-title":"Lancet"},{"issue":"26","key":"3623_CR15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/nejmoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/nejmoa1804092.","journal-title":"N Engl J Med"},{"issue":"26","key":"3623_CR16","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/nejmoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385. https:\/\/doi.org\/10.1056\/nejmoa1804093.","journal-title":"N Engl J Med"},{"issue":"1","key":"3623_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s2213-2600(21)00322-2","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Ford LB, Maspero JF, et al. Longterm safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11\u201325. https:\/\/doi.org\/10.1016\/s2213-2600(21)00322-2.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"3623_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/cea.70005","volume":"55","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Zhong N, Dhooria S, et al. Dupilumab efficacy and safety in patients with persistent asthma: Asia-Pacific region. Clin Exp Allergy. 2025;55(8):691\u2013700. https:\/\/doi.org\/10.1111\/cea.70005.","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"3623_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","volume":"12","author":"D Chodankar","year":"2021","unstructured":"Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12(3):171\u20134. https:\/\/doi.org\/10.4103\/picr.picr_62_21.","journal-title":"Perspect Clin Res"},{"key":"3623_CR20","doi-asserted-by":"publisher","DOI":"10.54724\/lc.2024.e1","volume":"4","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, Park J, Kattih M, et al. Trends in prevalence of asthma and COVID-19 pandemic-related factors in South Korea: a post-hoc analysis. Life Cycle. 2024;4:e1. https:\/\/doi.org\/10.54724\/lc.2024.e1.","journal-title":"Life Cycle"},{"issue":"3","key":"3623_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s12325-022-02399-5","volume":"40","author":"R Gall","year":"2023","unstructured":"Gall R, Jain N, Soong W, et al. Dupilumab-treated patients with asthma in the real world: the RAPID global registry. Adv Ther. 2023;40(3):1292\u20138. https:\/\/doi.org\/10.1007\/s12325-022-02399-5.","journal-title":"Adv Ther"},{"issue":"2","key":"3623_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12325-024-03051-0","volume":"42","author":"NL Lugogo","year":"2025","unstructured":"Lugogo NL, Soler X, Gon Y, et al. Baseline characteristics of dupilumab-treated patients with asthma in the real world: the RAPID global registry. Adv Ther. 2025;42(2):849\u201362. https:\/\/doi.org\/10.1007\/s12325-024-03051-0.","journal-title":"Adv Ther"},{"issue":"4","key":"3623_CR23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902\u20137. https:\/\/doi.org\/10.1034\/j.1399-3003.1999.14d29.x.","journal-title":"Eur Respir J"},{"issue":"5","key":"3623_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","volume":"99","author":"EF Juniper","year":"2005","unstructured":"Juniper EF, Svensson K, M\u00f6rk A-C, St\u00e5hl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553\u20138. https:\/\/doi.org\/10.1016\/j.rmed.2004.10.008.","journal-title":"Respir Med"},{"issue":"1","key":"3623_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40629-016-0006-7","volume":"26","author":"L Klimek","year":"2017","unstructured":"Klimek L, Bergmann KC, Biedermann T, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017;26(1):16\u201324. https:\/\/doi.org\/10.1007\/s40629-016-0006-7.","journal-title":"Allergo J Int"},{"issue":"5","key":"3623_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447\u201354. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x.","journal-title":"Clin Otolaryngol"},{"issue":"12","key":"3623_CR27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139. https:\/\/doi.org\/10.1001\/archderm.140.12.1513.","journal-title":"Arch Dermatol"},{"issue":"1","key":"3623_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","volume":"67","author":"ME Schram","year":"2012","unstructured":"Schram ME, Spuls PI, Leeflang MMG, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99\u2013106. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02719.x.","journal-title":"Allergy"},{"issue":"2","key":"3623_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4046\/trd.2024.0198","volume":"88","author":"D Larenas-Linnemann","year":"2025","unstructured":"Larenas-Linnemann D, Rhee CK, Altraja A, et al. International Severe Asthma Registry (ISAR): 2017-2024 status and progress update. Tuberc Respir Dis. 2025;88(2):193\u2013215. https:\/\/doi.org\/10.4046\/trd.2024.0198.","journal-title":"Tuberc Respir Dis"},{"issue":"10","key":"3623_CR30","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/all.16178","volume":"79","author":"E Denton","year":"2024","unstructured":"Denton E, Hew M, Peters MJ, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024;79(10):2700\u201316. https:\/\/doi.org\/10.1111\/all.16178.","journal-title":"Allergy"},{"key":"3623_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108199","volume":"245","author":"TR Tay","year":"2025","unstructured":"Tay TR, Pang PH, Liew MF, et al. Ethnic variation in South East Asian patients with severe asthma: a first look at the Singapore Severe Asthma Registry (SSAR) and implications on clinical practice. Respir Med. 2025;245:108199. https:\/\/doi.org\/10.1016\/j.rmed.2025.108199.","journal-title":"Respir Med"},{"issue":"1","key":"3623_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0871-1","volume":"19","author":"H Neffen","year":"2019","unstructured":"Neffen H, Moraes F, Viana K, et al. Asthma severity in four countries of Latin America. BMC Pulm Med. 2019;19(1):123. https:\/\/doi.org\/10.1186\/s12890-019-0871-1.","journal-title":"BMC Pulm Med"},{"key":"3623_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106586","volume":"187","author":"M Al-Ahmad","year":"2021","unstructured":"Al-Ahmad M, Nurkic J, Othman Y, Jusufovic E, Maher A. Severe asthma in Kuwait population: phenotype-based approach. Respir Med. 2021;187:106586. https:\/\/doi.org\/10.1016\/j.rmed.2021.106586.","journal-title":"Respir Med"},{"issue":"4","key":"3623_CR34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/all.15992","volume":"79","author":"E Lee","year":"2024","unstructured":"Lee E, Rhee EH, Yu J, et al. Incidence of healthcare utilization for allergic and respiratory infectious diseases in children with asthma before and during the COVID-19 pandemic. Allergy. 2024;79(4):1064\u20137. https:\/\/doi.org\/10.1111\/all.15992.","journal-title":"Allergy"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03623-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03623-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:50Z","timestamp":1787385890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03623-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03623-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jorge F. M\u00e1spero is a consultant for AstraZeneca and Sanofi; has received speaker fees from GSK, Menarini, Novartis, and Uriach; and has received research grants from Novartis. Rand K. Arnaout has received honoraria for serving as a speaker and on advisory boards from AllergoTek, AstraZeneca, Biologix, GSK, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda. Leslie Vargas-Ram\u00edrez has served as a speaker for AstraZeneca, Boehringer Ingelheim, and GSK. Hassan Mobayed and Bassam Mahboub have no conflicts of interest to disclose. Carla Irani has received honoraria from Novartis, Sanofi, and Stallergenes Greer. Amir Bar-Shai reports advisory board member\/consulting fees, speaker fees, institutional research grants from AstraZeneca, Boehringer Ingelheim, GSK, Kamada, and Sanofi. Mariko S. Koh has received research support from AstraZeneca and reports lecture and advisory board honoraria paid to her institution from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Roche, and Sanofi. Jason Chao is a former employee of Sanofi and may hold stock and\/or stock options in the company. Sherif Zaghloul and Jennifer Dewhurst are employees of Sanofi and may hold stock and\/or stock options in the company. Jason H. Kwah is an employee and shareholder of Regeneron Pharmaceuticals Inc. Mona S. Al-Ahmad has received honoraria for serving as a speaker and on advisory boards from AstraZeneca, GSK, Novartis, and Sanofi.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"REVEAL is being conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. The REVEAL protocol was reviewed and approved by the respective institutional review boards before patient recruitment. All patients provided written informed consent. For patients under the age of 18 years, both parental\/legal guardian consent and patient assent were required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}